CHRS Coherus Oncology, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1512762 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY44.4%
TTM net income YoY-187.7%
TTM EPS YoY-175.2%
Revenue 3-yr CAGR-36.7%
Net income 3-yr CAGR—
Margins
Gross margin69.8%
Operating margin-275.9%
Net margin-253.4%
FCF margin—
EBITDA margin-274.3%
Returns
ROE-240.5%
ROA-39.5%
ROIC (approx.)—
Asset turnover0.16x
Leverage & solvency
Liabilities / assets85.2%
Debt / equity0.00x
Current ratio1.51x
Interest coverage-15.52x
Cash quality & payout
Operating cash flow / net income1.28x
Accruals ratio11.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $42.17M | $26.39M |
| Cost of revenue | $13.81M | $8.73M |
| Gross profit | $28.36M | $17.66M |
| R&D expense | $108.89M | $91.83M |
| SG&A expense | $100.60M | $125.48M |
| Operating income | -$181.13M | -$199.65M |
| Interest expense | $9.00M | $10.73M |
| Pretax income | -$183.12M | -$215.39M |
| Income tax | $0 | $0 |
| Net income | $168.02M | $28.51M |
| EBITDA | -$179.83M | -$198.05M |
| EPS (basic) | 1.43 | 0.25 |
| EPS (diluted) | 1.43 | 0.25 |
| Weighted avg. shares (diluted) | 117.14M | 114.55M |
| Balance sheet | ||
| Cash & equivalents | $88.88M | $126.25M |
| Short-term investments | $83.25M | — |
| Receivables | $17.82M | $111.32M |
| Inventory | $3.17M | $4.21M |
| Current assets | $206.71M | $341.58M |
| PP&E, net | $1.34M | $2.58M |
| Intangibles | $20.00M | $24.79M |
| Total assets | $258.34M | $448.53M |
| Current liabilities | $140.39M | $282.98M |
| Total liabilities | $197.33M | $580.52M |
| Shareholders' equity | $61.01M | -$131.99M |
| Shares outstanding | 121.15M | 115.61M |
| Cash flow statement | ||
| Operating cash flow | -$138.51M | -$20.44M |
| Investing cash flow | $375.09M | $230.32M |
| Financing cash flow | -$273.70M | -$186.97M |
| Depreciation & amortization | $1.30M | $1.60M |
| Stock-based compensation | $16.97M | $27.80M |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.